Ulrike Wehkemp

LY05 The plaque thickens: predictors of progression and prognosis in early-stage cutaneous T-cell lymphoma

Julia Scarisbrick, Abraham Bashir, S J Whittaker, Christiane Querfeld et autres

Abstract The PROspective Cutaneous Lymphoma International Prognostic Index Study ‘PROCLIPI’ (ClinicalTrials.Gov ID: NCT02848274) opened in 2015 at > 50 international expert centres for mycosis fungoides (MF) and Sézary syndrome (SS). The aim of the study was to determine a prognostic index to …

gb, th, us, nl, gr, fr, by, es, ch, br, au, de, at, be, it, fi, hu, ar, Égypte (code pays fourni par la source)

LY08 Real-world outcomes and survival with targeted and established systemic therapies in advanced-stage cutaneous T-cell lymphoma: an updated PROCLIPI analysis

Elizabeth Peterknecht, Abraham Bashir, Evangelina Papadavid, Alejandro Gru et autres

Abstract Brentuximab vedotin (BV), a CD30+ antibody conjugate, was approved for CD30+ cutaneous T-cell lymphoma in 2018. Mogamulizumab, an anti-CCR4 monoclonal antibody was approved for refractory mycosis fungoides and Sézary syndrome. The overall survival (OS) benefit and optimal sequencing of these therapies …

us, gb, gr, nl, fr, by, es, ch, br, au, de, at, be, it, fi, hu, ar, Égypte (code pays fourni par la source)

Real-World Survival with Mogamulizumab versus Brentuximab in Advanced CTCL: insights from PROCLIPI

Elizabeth Peterknecht, Evangelia Papadavid, Alejandro Ariel Gru, Sean J Whittaker et autres

A patchy prognosis: identification of prognostic factors associated with significant reduction in survival of early-stage Mycosis Fungoides patients

Julia Jane Scarisbrick, Sean J Whittaker, Christiane Querfeld, Maarten H. Vermeer et autres

Lymph node imaging and correlation with histological N-class: results from the PROCLIPI study show sum of the product of dimensions is the better predictor than single axis measurements

Jung U. Yoo, Martine Bagot, Emmilia Hodak, O. Servitige et autres